DYNC1LI1

Across TCGA pan-cancer cohorts, DYNC1LI1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated DYNC1LI1 data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DYNC1LI1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DYNC1LI1 expression acts as an unfavorable survival marker.

BLCA, ESCA, and COAD are the cancer types where DYNC1LI1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.246	0.606	.007	12	view →
ESCA	OS	Median	IV	0.095	0.512	.008	12	view →
COAD	OS	Median	All	0.594	0.870	.041	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

DYNC1LI1–BLCA (OS)

Open the BLCA breakdown →